Inozyme Pharma Inc (INZY)

$0.92 -0.04 (-4.40%)
Market Cap 59.07M
Revenue (ttm) 0.00
Net Income (ttm) -102.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.79
Volume 305,400
Avg Vol 518,530
Day's Range N/A - N/A
Shares Out 64.24M
Stochastic %K 55%
Beta 1.39
Analysts Strong Sell
Price Target $13.75

Latest News on INZY

Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency

Apr 10, 2025, 8:30 AM EDT - 10 days ago

Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency

Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 8:30 AM EDT - 20 days ago

Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference

Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights

Mar 10, 2025, 8:30 AM EDT - 5 weeks ago

Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights

Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 8:30 AM EST - 7 weeks ago

Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference

Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025

Feb 21, 2025, 8:30 AM EST - 2 months ago

Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025

Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 27, 2024, 8:30 AM EST - 5 months ago

Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference

Inozyme Pharma to Present at Upcoming Investor Conferences

Nov 11, 2024, 8:30 AM EST - 5 months ago

Inozyme Pharma to Present at Upcoming Investor Conferences

Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Nov 5, 2024, 8:30 AM EST - 5 months ago

Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701

Oct 24, 2024, 1:15 PM EDT - 6 months ago

Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701

Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024

Oct 17, 2024, 8:30 AM EDT - 6 months ago

Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024

Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors

Oct 7, 2024, 8:30 AM EDT - 6 months ago

Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors

Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look'

Sep 12, 2024, 2:35 PM EDT - 7 months ago

Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look'

Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference

Aug 29, 2024, 8:30 AM EDT - 8 months ago

Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference

Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion

Jul 30, 2024, 1:56 PM EDT - 9 months ago

Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion

Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function

Jul 25, 2024, 8:30 AM EDT - 9 months ago

Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function

Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency

Jul 2, 2024, 8:30 AM EDT - 10 months ago

Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency

Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children's Bone Health (ICCBH)

Jun 21, 2024, 1:00 PM EDT - 10 months ago

Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children's Bone Health (ICCBH)

Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences

May 23, 2024, 8:30 AM EDT - 11 months ago

Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences

Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference

May 8, 2024, 8:30 AM EDT - 1 year ago

Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference

Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights

May 7, 2024, 8:30 AM EDT - 1 year ago

Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 3, 2024, 8:30 AM EDT - 1 year ago

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

Apr 8, 2024, 6:30 AM EDT - 1 year ago

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference

Apr 2, 2024, 8:30 AM EDT - 1 year ago

Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference

Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024

Mar 26, 2024, 8:30 AM EDT - 1 year ago

Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024

Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

Mar 12, 2024, 8:30 AM EDT - 1 year ago

Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward

Mar 8, 2024, 2:45 PM EST - 1 year ago

Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward

Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 8:30 AM EST - 1 year ago

Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference

Inozyme: A Major Catalyst Is Uncomfortably Far Off

Nov 27, 2023, 7:30 AM EST - 1 year ago

Inozyme: A Major Catalyst Is Uncomfortably Far Off

Inozyme Pharma to Participate in Upcoming Investor Conferences

Nov 9, 2023, 8:30 AM EST - 1 year ago

Inozyme Pharma to Participate in Upcoming Investor Conferences

Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights

Nov 7, 2023, 8:30 AM EST - 1 year ago

Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights

Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England's Generation Study of Rare Conditions

Oct 10, 2023, 8:30 AM EDT - 1 year ago

Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England's Generation Study of Rare Conditions

Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting

Oct 6, 2023, 8:30 AM EDT - 1 year ago

Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting

Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023

Sep 20, 2023, 8:30 AM EDT - 1 year ago

Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023

Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 5, 2023, 8:30 AM EDT - 1 year ago

Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights

Aug 8, 2023, 8:30 AM EDT - 1 year ago

Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights

Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock

Aug 1, 2023, 4:01 PM EDT - 1 year ago

Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock

Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock

Jul 27, 2023, 11:20 PM EDT - 1 year ago

Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock

Inozyme Pharma, Inc. Announces Proposed Offering of Common Stock

Jul 27, 2023, 4:33 PM EDT - 1 year ago

Inozyme Pharma, Inc. Announces Proposed Offering of Common Stock

Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency

Jul 26, 2023, 7:30 AM EDT - 1 year ago

Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency

Inozyme Pharma to Provide ENPP1 Deficiency Program Update on July 26, 2023

Jul 19, 2023, 8:30 AM EDT - 1 year ago

Inozyme Pharma to Provide ENPP1 Deficiency Program Update on July 26, 2023

Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701

Jun 27, 2023, 8:30 AM EDT - 1 year ago

Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701

Inozyme Pharma to Present at the Jefferies Healthcare Conference

Jun 2, 2023, 7:30 AM EDT - 2 years ago

Inozyme Pharma to Present at the Jefferies Healthcare Conference

Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights

May 9, 2023, 8:30 AM EDT - 2 years ago

Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights

Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)

Apr 14, 2023, 8:30 AM EDT - 2 years ago

Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)

Inozyme Pharma to Participate at the 22nd Annual Needham Virtual Healthcare Conference

Apr 11, 2023, 8:30 AM EDT - 2 years ago

Inozyme Pharma to Participate at the 22nd Annual Needham Virtual Healthcare Conference

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Operations Officer

Apr 4, 2023, 8:30 AM EDT - 2 years ago

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Operations Officer

Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights

Mar 22, 2023, 8:30 AM EDT - 2 years ago

Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights

Inozyme Pharma to Participate in the Cowen 43rd Annual Health Care Conference

Mar 1, 2023, 8:30 AM EST - 2 years ago

Inozyme Pharma to Participate in the Cowen 43rd Annual Health Care Conference

Inozyme Pharma: Rare Disease Player Merits Revaluation Higher After POC Data

Feb 21, 2023, 4:51 PM EST - 2 years ago

Inozyme Pharma: Rare Disease Player Merits Revaluation Higher After POC Data